Edition:
United States

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

1.52USD
20 Apr 2018
Change (% chg)

$0.06 (+4.11%)
Prev Close
$1.46
Open
$1.52
Day's High
$1.52
Day's Low
$1.52
Volume
4,021
Avg. Vol
70,909
52-wk High
$4.25
52-wk Low
$0.63

Latest Key Developments (Source: Significant Developments)

Capricor Q4 Earnings Per Share $0.42
Wednesday, 14 Mar 2018 04:00pm EDT 

March 14 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE.Q4 EARNINGS PER SHARE $0.42.CAPRICOR THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS,MARKETABLE SECURITIES TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OTHERSTHROUGH Q4 OF 2018.  Full Article

Capricor Therapeutics Says ‍FDA Has Granted CAP-1002 RMAT Designation
Monday, 5 Feb 2018 07:13am EST 

Feb 5 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS SAYS ‍FDA HAS GRANTED CAP-1002 REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION - SEC FILING.  Full Article

Capricor Therapeutics Appoints Anthony Bergmann As CFO, Eff Jan 1, 2018 - SEC Filing
Friday, 22 Dec 2017 04:29pm EST 

Dec 22 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS INC SAYS HAS APPOINTED ANTHONY BERGMANN AS CHIEF FINANCIAL OFFICER, EFFECTIVE JANUARY 1, 2018 - SEC FILING.CAPRICOR THERAPEUTICS INC - ON DEC 20, LELAND GERSHELL GAVE NOTICE OF HIS RESIGNATION AS CHIEF FINANCIAL OFFICER OF COMPANY, EFFECTIVE JANUARY 1, 2018.  Full Article

Capricor & California Institute For Regenerative Medicine​ Entered Into Amendment 3 To CIRM Notice Loan Award
Tuesday, 12 Dec 2017 09:41am EST 

Dec 12 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR SAYS ‍ON DEC 11, CO, CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE​ ENTERED INTO AMENDMENT NO. 3 TO CIRM NOTICE OF LOAN AWARD - SEC FILING.CAPRICOR SAYS PURSUANT TO AMENDMENT, TOTAL LOAN BALANCE UNDER LOAN AWARD FORGIVEN BY CIRM, TERMINATING UNIT, CO'S OBLIGATION TO REPAY LOAN BALANCE​.CAPRICOR - ‍DECISION TO TERMINATE LOAN AWARD AND FORGIVE LOAN BALANCE WAS DUE TO ABANDONMENT OF ALLSTAR PROJECT AT END OF PROJECT PERIOD​.  Full Article

Capricor Therapeutics Says FDA Cleared IND Application For CAP-1002
Wednesday, 29 Nov 2017 07:00am EST 

Nov 29 (Reuters) - Capricor Therapeutics Inc ::CAPRICOR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR CAP-1002.CAPRICOR THERAPEUTICS INC - POTENTIAL REGISTRATION TRIAL IN DUCHENNE MUSCULAR DYSTROPHY ON TRACK TO INITIATE IN Q1 OF 2018.CAPRICOR THERAPEUTICS-PLANS TO APPLY FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR CAP-1002 BASED ON UPDATED GUIDANCE RECENTLY ISSUED BY FDA.  Full Article

Capricor Therapeutics reports Q3 loss per share $0.12
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Capricor Therapeutics Inc ::Capricor Therapeutics reports third quarter 2017 financial results and provides update on duchenne muscular dystrophy development program.Q3 loss per share $0.12.  Full Article

Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at WMS International Congress
Wednesday, 4 Oct 2017 07:00am EDT 

Oct 4 (Reuters) - Capricor Therapeutics Inc : :Capricor Therapeutics presents positive six-month results in duchenne muscular dystrophy at World Muscle Society International Congress.Capricor Therapeutics Inc - ‍treatment with CAP-1002 was generally safe and well-tolerated over initial six-month follow-up period of hope trial​.  Full Article

Capricor Therapeutics Q2 loss per share $0.16
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Capricor Therapeutics Inc :Capricor Therapeutics reports second quarter 2017 financial results and provides corporate update.Q2 loss per share $0.16.Capricor Therapeutics Inc - announced statistically-significant improvements in skeletal and cardiac muscle function in patients treated with CAP-1002.Capricor Therapeutics Inc - plans to commence clinical trial of I.V. CAP-1002 in Duchenne Muscular Dystrophy in the fourth quarter.  Full Article

Capricor Therapeutics files for resale of up to 1.2 mln shares of co's common stock by the selling stockholders - SEC Filing
Friday, 7 Jul 2017 06:14am EDT 

July 7 (Reuters) - Capricor Therapeutics Inc :Capricor Therapeutics Inc files for resale of up to 1.2 million shares of co's common stock by the selling stockholders - SEC Filing.Capricor Therapeutics Inc says co will not receive any proceeds from sale of common stock by the selling stockholders.  Full Article

Capricor Therapeutics retains full rights to CAP-1002 as Janssen Biotech decides not to exercise option
Thursday, 6 Jul 2017 06:30pm EDT 

July 6 (Reuters) - Capricor Therapeutics Inc ::Capricor therapeutics- no payments between capricor and janssen are required to be made in relation to this decision.Capricor therapeutics retains full rights to cap-1002 as janssen biotech, inc. Decides not to exercise option.Capricor therapeutics inc-in connection with decision, collaboration agreement, license option entered into between co and janssen terminated.Capricor therapeutics inc-no payments between capricor and janssen are required to be made in relation to decision.Capricor therapeutics-co to have fully paid-up non-exclusive license under patents controlled by janssen utilized in production of clinical trial materials.Capricor therapeutics-to have non-exclusive license to publish, disclose, use information of janssen utilized in production of clinical trial materials.  Full Article

BRIEF-Capricor Q4 Earnings Per Share $0.42

* CAPRICOR PRESENTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE UPDATE